Chardan Capital Markets Downgrades Clearside Biomedical (CLSD) to Neutral
Tweet Send to a Friend
Chardan Capital Markets analyst Daniil Gataulin downgraded Clearside Biomedical (NASDAQ: CLSD) from Buy to Neutral.The analyst comments: "On 17 July ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
